Herbacetin suppressed MMP9 mediated angiogenesis of malignant melanoma through blocking EGFR-ERK/AKT signaling pathway

Copyright © 2019 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved..

Malignant melanoma remains a challenge for clinical practice and novel therapeutic strategies are urgently needed. Herbacetin, a natural flavonoid compound that has multiple pharmacological activities, exerts anticancer effects on several human tumors. In this study, the anti-angiogenesis effect of Herbacetin in human malignant melanoma was investigated. The results indicated that Herbacetin treatment significantly suppressed tumor growth and angiogenesis of malignant melanoma both in vitro and in vivo. In melanoma A375 and Hs294T cells, Herbacetin treatment suppressed both EGF-induced and constitutive phosphorylation of EGFR, accelerated the internalization and degradation of EGFR, and subsequently suppressed the activation of the downstream kinases (AKT and ERK). Moreover, MMP9 was determined as a key angiogenic factor in Herbacetin treated melanoma cells. Knockdown of MMP9 suppressed the in vitro angiogenesis while overexpression of MMP9 in Herbacetin treated melanoma cells restored the angiogenesis ability. We concluded that Herbacetin suppressed melanoma angiogenesis through blocking EGFR-ERK/AKT-MMP9 signaling pathway and Herbacetin may be developed as a potential drug for melanoma treatment.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:162

Enthalten in:

Biochimie - 162(2019) vom: 15. Juli, Seite 198-207

Sprache:

Englisch

Beteiligte Personen:

Li, Lei [VerfasserIn]
Fan, Pengfei [VerfasserIn]
Chou, Haiyan [VerfasserIn]
Li, Juan [VerfasserIn]
Wang, Kai [VerfasserIn]
Li, Hao [VerfasserIn]

Links:

Volltext

Themen:

62229-50-9
Angiogenesis
Angiogenesis Inhibitors
EC 2.7.10.1
EC 3.4.24.35
EGFR protein, human
EGFR-ERK/AKT
Epidermal Growth Factor
ErbB Receptors
Flavonoids
Herbacetin
Journal Article
MMP9
MMP9 protein, human
Malignant melanoma
Matrix Metalloproteinase 9

Anmerkungen:

Date Completed 09.12.2019

Date Revised 13.12.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.biochi.2019.05.003

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM296944386